CD4 and cancer: It follows that those with immunocompromise in this trial including HIV with CD4 count <200 and malignancy were associated with unfavorable outcome defined as death or survival with relapse or sequelae.11 Interestingly, in this analysis, there was no significant difference in outcomes for those with less overt forms of immunocompromise such as cirrhosis, renal disease, alcoholism, diabetes, or immunosuppressive dose of corticosteroids.